UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000036177
Receipt No. R000041215
Scientific Title Evaluation of cognitive function maintenance or improvement effect of propolis-containing food in healthy adults
Date of disclosure of the study information 2021/01/01
Last modified on 2021/03/11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of cognitive function maintenance or improvement effect of propolis
Acronym Evaluation of cognitive function maintenance or improvement effect of propolis
Scientific Title Evaluation of cognitive function maintenance or improvement effect of propolis-containing food in healthy adults
Scientific Title:Acronym Evaluation of cognitive function maintenance or improvement effect of propolis-containing food in healthy adults
Region
Japan

Condition
Condition Adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 We examine the maintenance or improvement effect of cognitive function and the safety when the elderly subjects take propolis for 24 weeks.
Efficacy is confirmed by comparing the cognitive function score of the propolis group and the placebo group in 24 weeks after taking. Also, confirm safety by evaluating physiological test, hematological test, blood biochemical test, urinalysis and adverse events.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Cognitrax (total score of verbal memory, visual memory, finger swing, SDC, stroop, attention shift, persistent processing and 4 part sustained processing)
Measuring before intake and 24 weeks after intake.
Key secondary outcomes MMSE, VAS on forgetfulness and markers related inflammation and heavy metal.
Measuring before intake and 24 weeks after intake.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Placebo
Intake: 0 mg
Ingesion: 168 days
Interventions/Control_2 Propolis
Intake: 542.88 mg
Ingesion: 168 days
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
60 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1. Healthy Japanese men and women aged greater than or equal to 60 years, less than 80 years at the time of obtaining informed consent.
2. Subjects with MMSE score of 24 to 29 at screening.
3. Subjects who have subjective forgetfulness or have been pointed out forgetfulness by others.
4. Subjects who normally take three meals a day.
5. Subjects who got adequate explanation about the purpose and details of the examination, have the capacity to consent, voluntarily participate in understanding, and agree to participate in the examination in writing.
Key exclusion criteria 1. Subjects who judged by a doctor as dementia.
2. Subjects who have taken or had taken drugs of dementia or drugs affecting cognitive function
3. Subjects who have current medical history or past medical history of mental disorders (including depressive symptoms) or cerebrovascular diseases.
4. Subjects who regularly use supplements or health foods that may affect cognitive functions.
5. Subjects who judged inappropriate as subjects as a result of clinical examination of screening 1 or brain MRI examination of screening 2.
6. Subjects who were extremely irregular in their lifestyle such as meals or sleeping.
7. Subjects who have a history of asthma or current medical history.
8. Subjects who have allergies to bee products (honey etc.), conifers, trees of Pinaceae, poplar and salicylic acid.
9. Subjects who have history of alcohol dependence or current medical history.
10. Subjects who consume a large amount of alcohol routinely
11. Subjects who have serious illness or medical history such as diabetes, liver disease, kidney disease, heart disease.
12. Subjects who have medical history or history of food allergies or current medical history.
13. Subjects who have take warfarin potassium
14. Subjects who have gerontological depression scale (GDS-S-J) score of 6 or more
15. Subjects who have color vision disorder and can not easily hear people's talk at short distance.
16. Subjects who have problems with the functions of both hands due to injury, surgery, etc.
17. Participating in other food intake, testing using medicines, applying cosmetics and medicines etc, person participating in other studies during participation in this study, consent acquisition within 1 month For other exams Participants
18. Others who judged that the investigator is inappropriate as the subject
Target sample size 90

Research contact person
Name of lead principal investigator
1st name Yoshitaka
Middle name
Last name Iwama
Organization Nihonbashi Cardiology Clinic
Division name Director
Zip code 103-0001
Address Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
TEL 03-5641-4133
Email yiwama@well-sleep.jp

Public contact
Name of contact person
1st name Yoshika
Middle name
Last name Komori
Organization KSO Corporation
Division name Sales department
Zip code 105-0023
Address Shibaura OMODAKA Bldg. 7F, 1-9-7 Shibaura, Minato-ku, Tokyo
TEL 03-3452-7733
Homepage URL
Email yoshi@kso.co.jp

Sponsor
Institute KSO Corporation
Institute
Department

Funding Source
Organization Yamada Bee Company, Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Research Center for Immunological Analysis. Inc.
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nihonbashi Cardiovascular Department Clinic Ethics Committee
Address Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
Tel 03-5641-4133
Email yiwama@ well-sleep.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 01 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 03 Month 11 Day
Date of IRB
2019 Year 03 Month 11 Day
Anticipated trial start date
2019 Year 05 Month 08 Day
Last follow-up date
2019 Year 11 Month 24 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 03 Month 12 Day
Last modified on
2021 Year 03 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041215

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.